The UK Myeloma Society (UKMS) launched the UKMS Pharmacy Group at the Spring Day 2022. The aim of the group is to promote excellence in the pharmaceutical care of patients with myeloma. The Group will support education, development of guidelines and will encourage cancer pharmacists to undertake high quality, audit and research (aligned with UKMS and UK Myeloma Research Alliance workplans).
Working closely with the UKMS Nurse Group they will also aim to promote standardisation of clinical practice across the UK. Initially the focus is on the use of DOACs as imid thromboprophylaxis and the use of bile acid sequestrants for lenalidomide induced diarrhoea.
More information about the UK Myeloma Society can be found here- https://www.ukmf.org.uk/ . You can join UKMS either via the form available on the website- https://www.ukmf.org.uk/join-the-ukmf/ or by contacting [email protected]. The Pharmacy Group report to the UKMS Executive Board:
We currently have over 40 members and an active email discussion forum – [email protected]